Skip to main content

Haematology Research Team

Overview of the Research

The Haematology Research Team is committed to providing patients with a high quality, professional and ethical research experience; delivered with care, compassion and respect. We promote an environment of mutual respect and communication between patients and staff.

The Haematology Research team run 27 trials ranging from multi-armed international randomised controlled trials, to service evaluations. We cover all areas of malignant haematology; acute and chronic leukaemia’s, high and low grade lymphomas and myeloma. We also run non-interventional studies in non-malignant haematology such as Haemophilia, which is an area we hope to expand.

As part of our trials, we are testing novel agents, with the aim of improving patient outcomes, giving patients access to treatments not yet available on the NHS. We provide close clinical monitoring of our patients, and from the results of our trials, patient care is constantly improving.

The team consists of 2 WTE Research Nurses, 0.4 WTE Epidemiology Trials Assistant, and 0.2 WTE Clinical Trials Officer, as well as 5 consultants who are all research active.

The Research Team

Victoria Drew

Lead Research Nurse

Sarah Matthews

Haematology Research Sister

Dr Suresh Kumar Krishnan

Dr Suresh Kumar Krishnan

Consultant Haematologist

Jannika Lazarte

Epidemiology Trials Assistant

Jane Sewell

Research Admin Assistant

Kelvin Stewart

Clinical Trials Officer

Dr Sam Ackroyd

Consultant Haematologist and Haemophilia Director. Consultant Research Lead in Haematology

Dr Anshu Garg

Consultant Haematologist

Dr Adrian Williams

Consultant Haematologist

Abida Naeem

Abida Naeem

Consultant Haematologist

Our Research 


AML 18.– First line treatment for new AMLs over 65 years of age

AML 19 – First line treatment for new AMLs under 65 years of age

APL-DIC – Understanding and managing the coagulopathy of APL – pilot study.

LI-1 – Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial

Flair – First line treatment for CLL

ARROVEN – phase 4 study for Brentuximab

Horizons – Longditudinal QoL for NHL, Breat and Gynae patients.

CARES – Haemophillia carriers well being study

CALLS – Mutation analysis in CML and PH+ve ALL

PRAN 16-52 – Placebo controlled study in non-transplant AML

REALISM – retrospective data collection in myelofibrosis

Late effects in Hodgkin’s Lymphoma – retrospective data collection for HL patients treated with radiotherapy

MOL-GEN – Molecular genetics study for patients with Bleomycin toxity

MDS registry – A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes

EBV associated NK/T cell malignancies – Study of EBV associated NK/T cell diseases and formation of a registry

UKAITR – United Kingdom Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry: An Investigation of Disease Progression, Treatment Effectiveness, and Co-morbid Conditions

UKALL 14 – A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

UKALL 60+ – A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia


AML 17 – Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17

MYELOMA XI – Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide

PACIFICO – Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)

Lymphoma and myeloma: promoting early diagnosis – Lymphoma and myeloma: Understanding the patient pathway and promoting early diagnosis

InCiTE – Intracranial haemorrhage in thrombocytopenic haematology patients – Intracranial Haemorrhage in Thrombocytopenic Haematology Patients. A case control Study

FCLL – Genetic Study of Familial Chronic Lymphocytic Leukaemia and other Lymphoproliferative Disease (FCLL Study)


BRIGHTLIGHT: The 2012 TYA Cancer Cohort Study Do specialist cancer services for teenagers and young adults (TYA) add value?

REMoDL-B – A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib

RiALtO – A Randomised Investigation of Alternative Ofatumumab containing regimens in less fit patients with CLL

TEAMM – Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections


  • .

AML15 – A trial comparing different chemotherapy drug combinations with or without Mylotarg for acute myeloid leukaemia.

Bortezomib Study – A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomiib in relapsed mantle cell lymphoma

Myeloma IX – A phase III randomised open factorial trial, comprising an Intensive Pathway for younger/fitter patients where intensive high dose treatment with stem cell support is considered appropriate, and a Non-Intensive Pathway for older/less fit pati

NSHLG – National Study of Hodgkin’s Lymphoma Genetics

Quality of life in multiple myeloma and follicular lymphoma

PT-1 An open label phase III randomised trial with 3 groups of patients; low, intermediate and high to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary Thr

Myeloma X A comparison of high versus low-dose alkylating agent consolidation regimens for relapsed multiple myeloma

Mantle Cell Phase III Trial – A phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma

CML Registry A prospective registry of CML for Northern England and North Wales

European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy –

AML16 A Programme of Development for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastc Syndrome.

R-CODOX-M/IVAC A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt’s Lymphoma (BL) of International Prognostic Index (IPI) High or High I

R-CHOP 14 vs 21- first line treatment for newly diagnosed DLBCL patients undergoing R-CHOP chemotherapy

Spirit 1 A phase III, prospective randomised comparison of imatinib 400mg versus imatinib 800mg versus imatinib plus pegylated interferon in patients with newly-diagnosed chronic myeloid leukaemia.

Spirit 2 A phase III, prospective randomised comparison of imatinib 400mg daily versus dasatinib 100mg in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.


Myeloma IX into Myeloma XI

by: Victoria Drew, 01274 383438,

As part of the Haematology Research Team’s portfolio of trials, we have run Myeloma IX (which closed several years ago, but we are still following up the surviving patients), and Myeloma XI, which we are currently recruiting to. (Myeloma X is a trial for relapsed myeloma patients and is also currently recruiting).

Myeloma is a malignant disorder of plasma cells which is characterised by an excess of abnormal plasma cells, lytic bone lesions and paraproteins in the serum and urine, the majority of cases occurring over the age of 60.  It is an incurable condition which, in the absence of treatment, has a very poor prognosis.  With modern treatments the median overall survival is approximately 4-5 years (Morgan et al, 2011).

Myeloma IX examined a traditional chemotherapy regime and a thalidomide-based induction regime, and maintenance regimens as well as intravenous zoledronic acid and oral clodronate in patients with newly diagnosed multiple myeloma.  Overall survival and skeletal-related event data have been reported for the overall trial population.

Patients were assigned to intensive or non-intensive treatment pathways and randomized to induction standard vs. a thalidomide containing regime.  Patients were also randomized to zoledronic acid or sodium clodronate.  The trial showed that all thalidomide-containing regimens had better efficacy than traditional regimens.

In subgroup analysis of both pathways, zolendronic acid improved overall survival versus clodronate in all patient groups, and most profoundly in patients with baseline bone disease or other skeletal related events  (Morgan et al, 2012).

Worldwide it is now widely accepted that the main induction regimen for patients going for transplantation will be a thalidomide-containing regimen.  In the UK, this will be CTD, (cyclophosphamide, thalidomide, dexamethasone) which is a direct result of the Myeloma IX trial.   For patients not fit for transplantation, the results of Myeloma IX showed CTDa (drugs as above, but attenuated) was superior in its responses.

This was also the first study comparing bisphosphonates head to head (Morgan et al, 2012), and as a result, all newly diagnosed myeloma patients are now treated with zoledronic acid.

Clinical trials do not always prove that the ‘new’ or ‘intervention arm’ is better.   In Myeloma IX, maintenance thalidomide was shown to be no better than no maintenance in improving overall survival, therefore no further treatment is given after induction in standard care.

Myeloma IX’s results have determined the design for Myeloma XI; the standard arms are now CTD(a) vs. new anti-myeloma drugs (lenalidomide and velcade), as well as no maintenance vs. lenalidomide and vorisostat maintenance.  This trial opened in 2010 and is due to complete recruitment in 2014.


Morgan, G.J.  et al (2011) Myeloma XI protocol –  Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations, and maintenance lenalidomide (not published).

Morgan GJ, Davies FE,  Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA (2012)  Abstract from;   Accessed on 09 May 2012